CELLINK/BICO $159M Rev Bioink Market $999M by 2032 ARPA-H PRINT $65M Federal Grant 3D Bioprinting $5.6B by 2033 Bioink CAGR 14.2% - - Fastest Segment CollPlant CELLINK $2.8B Breast Implant Market Organ-on-Chip $952M by 2030 FDAMA 3.0 Dec 16, 2025 48,000+ BICO Instruments 65 Countries 11,900+ Research Citations CELLINK/BICO $159M Rev Bioink Market $999M by 2032 ARPA-H PRINT $65M Federal Grant 3D Bioprinting $5.6B by 2033 Bioink CAGR 14.2% - - Fastest Segment CollPlant CELLINK $2.8B Breast Implant Market Organ-on-Chip $952M by 2030 FDAMA 3.0 Dec 16, 2025 48,000+ BICO Instruments 65 Countries 11,900+ Research Citations

Domain Investment Thesis

The Consumable Layer of a $5.6B Industry

3D bioinks are the recurring-revenue material that every bioprinter consumes. Like reagents in genomics or toner in printing - - the razor needs blades. The global bioink market is the fastest-growing segment in bioprinting, and FDAMA 3.0 just made it mandatory.

$225M

Bioink Market 2024

Maximize Market Research

$999M

Bioink Market 2032

Maximize Market Research

20.48%

Bioink CAGR

2024- - 2032

48K+

Instruments Installed

BICO Group 2025

01 / Corporate Landscape

Who's Buying, Building, and Funding Bioinks

BICO Group (CELLINK)

World's first universal bioink. 48K+ instruments, 3,500 labs, 65 countries. Used by top 20 pharma. Nasdaq-listed.

$159M rev

3D Systems

NextGen Bioprinting Platform (May 2025). Basel point-of-care facial implant (March 2025). Organ-on-chip expansion.

$440M rev

Aspect Biosystems

Bioprinted tissue therapeutics. Proprietary bioink tech for organ-on-chip drug testing. Major pharma partnerships.

$100M+ raised

CollPlant Biotech

rhCollagen bioinks. CELLINK partnership for regenerative breast implants in $2.8B market. Plant-derived collagen.

Nasdaq: CLGN

TheWell Bioscience

VitroINK - - no crosslinking, no UV, no heat curing needed. Distributed by REGEMAT 3D. Feb 2025 launch.

Novel bioink

BIO INX

READYGEL INX gel-MA bioink for Readily3D volumetric printing. First commercial bioink for volumetric technology.

2025 launch

ARPA-H (US Gov)

PRINT program: $65M for bioprinted liver, kidney, heart constructs. Federal demand signal for advanced bioinks.

$65M grant

Generate:Biomedicines Novartis

$1B deal marrying AI protein design with bioprinting scaffolds. Bioink formulation is a core deliverable.

$1B deal

02 / Bioink Applications

Every Application Requires the Material

Drug Discovery

Bioprinted tissue models for preclinical testing. Replaces animal models under FDAMA 3.0 mandate.

Organ-on-Chip

Bioink-fabricated tissue layers on microfluidic devices. $952M market by 2030. FDA-endorsed alternative.

Tissue Engineering

Functional vascular grafts, bone scaffolds, cartilage. Symvess: first FDA-cleared tissue-engineered vascular graft, Dec 2024.

Regenerative Implants

Patient-specific orthopedic implants. Point-of-care facial implant at Basel (March 2025). 33.9% of market.

Cosmetic Testing

Bioprinted skin models replacing animal testing. L'Oreal, Shiseido adopting bioink-based assays. Regulatory-driven adoption.

Personalized Medicine

Patient-derived tumor models for drug sensitivity screening. POSTECH: 90% viability on gastric-cancer constructs.

Acquire 3DBioinks.com

The category-defining plural .com for the consumable powering regenerative medicine.

Inquire About This Domain

Acquire This Domain

Own 3dbioinks

This premium domain is available for acquisition. Perfect for companies, startups, or investors in this space.

Submit your inquiry below and we'll respond within 24 hours.